Coronary/Structural Heart Boston Scientific says Lotus out until Next Year Share by Ken Dropiewski on February 2, 2018 More in Coronary/Structural Heart: Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 August 31, 2026 Lapsi Health and the Mexican Society of Cardiology Announce Strategic Collaboration to Expand Access to Cardiovascular Clinical Guidance Through Keikku August 31, 2026 Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure August 31, 2026 Share this story Facebook Twitter LinkedIn Lotus Valve to Stay Off the Shelves Through 2018 Patrice Wendling – February 01, 2018, Medscape MARLBOROUGH, MA — The beleaguered Lotus heart valve system is not expected to launch in the US market until 2019, according to Boston Scientific officials. All Lotus valves were voluntarily recalled worldwide in February 2017 because of reports of early release of a pin connecting the transcatheter valve to the delivery system…. Read Full Article at Medscape here